Pipeline

Drug Device Combination
  Indication PreclinicAL Phase 1 Phase 2 Phase 3 Development status
MDR-100/200
  • DFU
  • Diabetic Neuropathy
  • Diabetic Polyneuropathy (DPN)
  • Hind Limb Ischemia
 
 
 
  • - Initial validation of animal PoC complete
  • - Validation with larger animal models completed
MDR-300
  • Type 1 Diabetes (T1DM)
 
 
 
  • - Initial validation of animal PoC complete
  • - Compassionate use trial (involving diabetic patients) in the planning process
MDR-400
  • Amyotrophic Lateral Sclerosis (ALS)
 
 
 
  • - Initial validation of animal PoC complete
TNT Drug Delivery System (The “device”)
  • Ischemia
  • DFU
  • DNP
  • TIDM
  • ALS
 
 
 
  • - Studies on precise dose control is ongoing
  • - Optimization of wafer-scale fabrication for human use is ongoing
  • - Efforts to reduce power requirement to low voltage is ongoing
  • - The patentability of an injetable version with nano-syringes that can target deeper, faster, and more efficiently is being reviewed
  • - Different forms of electrical stimulation (such as wireless electroporation) is being explored
  • MDR-100

    MDR-100 is the genetic elements capable of converting somatic cells to endothelial cells. The efficacy has been confirmed with murine and porcine models of injury-induced ischemia.

  • MDR-200

    MDR-200 is an antisense oligo nucleotide capable of converting somatic cells to endothelial cells. The efficacy has been confirmed with murine and porcine models of injury-induced ischemia.

  • MDR-300

    MDR-300 is the genetic element capable of converting somatic cells to insulin-secreting like cells. The efficacy has been confirmed with murine models of Type 1 diabetes

  • MDR-400

    MDR-400 is the genetic element capable of converting somatic cells to neuronal cells. The efficacy has been confirmed with murine models of stroke.

Status Complete Complete In Preparation
Animal study/Human trial Mouse Porcine flap Porcine Human (compassionate use trial)
TNT Device version TNTR TNTPC TNTPC TNTPC
Cargo
  • MDR-100
  • MDR-200
  • MDR-300
  • MRR-400
  • MDR-100
  • MDR-200

Multiple indications with a potential to expand into other areas will increase the future value of company significantly.